Fig. 1: Generation of BA.4/5 mAbs.
From: Emerging variants develop total escape from potent monoclonal antibodies induced by BA.4/5 infection
a Live virus neutralization FRNT50 titres against Victoria (an ancestral SARS-CoV-2 isolate), BA.2, BA.4 and BA.5 viruses using serum from vaccine breakthrough BA.4/5 serum. b Sorting strategy for BA.4/5 specific B cells. c Heavy chain and light chain gene usage of potent BA.4/5 mAbs. d Number of somatic mutations found in BA.4/5 mAbs (n = 28 samples) compared to sets previously isolated from early pandemic (n = 20 samples), Beta (n = 27 samples), BA.1 (n = 28 samples) and BA.2 (n = 26 samples) infection, which have been previously reported36. Mean with SEM are shown, and p values were calculated by Mann–Whitney test. e Blocking of ACE2-S interaction by potent BA.4/5 mAbs.
